Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (2652)	2/10/2019 4:11:10 PM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 3559

REGN-SNY, IO breakout/split? Anyone with idea at what point SNY can develop their own anti-PD-1 or/and anti-CTLA-4 Abs, from Ablynx Abs platform?

To: Miljenko Zuanic who wrote (2652)	2/11/2019 3:40:25 PM
From: Miljenko Zuanic	Respond to of 3559

Worth to note than SNY did not opt-out from the HD cemiplimab/SD-C + Y in P2 NSCLC, with PDL-1 level at <50% (2L, after chemo): clinicaltrials.gov So, while SNY continue to be part of the Cemiplimab IO development program, for any Ex-IODeveopment candidate and or Second party candidate (like anti-CTLA-4 Ab) SNY still hold opt to license (post POC status), on REGN revised terms. Also, note that 4659 have extended T1/2 than Y, and Q6W as well as Q12W is real option, from efficacy point... not only safety (SAE rate).